Results 1 to 10 of about 47,845 (203)

Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis

Cell Communication and Signaling, 2022
Langerhans cell histiocytosis (LCH) is an inflammatory myeloid malignancy in the “L-group” histiocytosis. Mitogen-activated protein kinase (MAPK) pathway activating mutations are detectable in nearly all LCH lesions. However, the pathogenic roles of MAPK
Xue-min Gao, Jian Li, Xin-xin Cao
doaj   +2 more sources

Adult-onset perianal Langerhans cell histiocytosis presenting as pruritus ani: a case report and review of the literature

Journal of Medical Case Reports, 2021
Background Langerhans cells belong to the histiocytic system and give rise to two tumors: Langerhans cell histiocytosis and Langerhans cell sarcoma. Clinical aggressiveness and degree of atypia distinguish the two neoplasms. Langerhans cell histiocytosis
Marah Hamdan, Jesse C. Qiao, Vid Fikfak
doaj   +2 more sources

Langerhans cell histiocytosis present in a 1-day-old girl: a case report [PDF]

Journal of Medical Case Reports
Background Langerhans cell histiocytosis is a rare condition characterized by diverse clinical manifestations, ranging from cutaneous lesions to systemic involvement.
Yang Meng
doaj   +2 more sources

Langerhans cell histiocytosis on the penis: a case report [PDF]

BMC Urology, 2006
Background Langerhans cell histiocytosis affects mainly young children and features an accumulation of CD1a+ dendritic Langerhans cells in the bone, skin, and other organs.
Kuroda Isao, Ashimine Satoshi, Ueno Munehisa, Hagiuda Jun, Ishizawa Keisuke, Deguchi Nobuhiro   +5 more
doaj   +4 more sources

A case of diagnosis and treatment of mediastinal Langerhans cytosis [PDF]

Journal of Cardiothoracic Surgery
Background Langerhans cell histiocytosis (LCH) is a rare disease. It mainly involves abnormal proliferation and aggregation of Langerhans cells, a type of cell of the immune system.Langerhans cytosis is more common in the bone, but it has rarely been ...
Yumeng Niu, Lei Xian, Yi Wang, Yourong Chen, Yifei Lu, Daying Liang   +5 more
doaj   +2 more sources

Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders

Haematologica, 2023
The standard treatment for Langerhans cell histiocytosis (LCH) is chemotherapy, although the failure rates are high. Since MAP-kinase activating mutations are found in most cases, BRAF- and MEK-inhibitors have been used successfully to treat patients ...
E. Cournoyer, Justin Ferrell, Susan Sharp, Anish Ray, Michael Jordan, C. Dandoy, M. Grimley, Somak Roy, Robert Lorsbach, A. C. Merrow, Adam Nelson, Allison L Bartlett, J. Picarsic, Ashish R Kumar   +13 more
semanticscholar   +1 more source

Establishment of MOS-SF36 percentile ranks in the general youth French population

BMC Psychology, 2022
Background The SF-36 is a generic quality of life questionnaire, massively translated and widely used to obtain physical and mental health status. However, validation work in the French language was carried out over a generation ago.
Arthur Trognon, Emilie Tinti, Blandine Beaupain, Jean Donadieu, Michel Musiol   +4 more
doaj   +1 more source

International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults

Blood, 2022
Langerhans cell histiocytosis (LCH) can affect children and adults with a wide variety of clinical manifestations, including unifocal, single-system multifocal, single-system pulmonary (smoking-associated), or multisystem disease.
G. Goyal, A. Tazi, R. Go, Karen L. Rech, J. Picarsic, R. Vassallo, Jason R. Young, C. Cox, J. V. van Laar, M. Hermiston, Xin-xin Cao, P. Makras, G. Kaltsas, J. Haroche, M. Collin, K. McClain, E. Diamond, M. Girschikofsky   +17 more
semanticscholar   +1 more source

Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis

American journal of hematology/oncology, 2021
Adult Langerhans cell histiocytosis (LCH) remains poorly defined. We retrospectively studied 266 newly diagnosed LCH patients to understand the clinical presentation, treatment, and prognosis of adult LCH. The median age at diagnosis was 32 years (range,
Xin-xin Cao, M. Duan, A. Zhao, H. Cai, Jia Chen, Xue-min Gao, Ting Liu, H. Cai, Lu Zhang, Jian Sun, Z. Liang, Dao-bin Zhou, Jian Li   +12 more
semanticscholar   +1 more source

Langerhans cell histiocytosis: Version 2021

Hematological Oncology, 2021
Children with Langerhnans cell histiocytosis (LCH) develop granulomatous lesions with characteristic clonal CD207+ dendritic cells that can arise as single lesions or life‐threatening disseminated disease. Despite the wide range of clinical presentations,
N. Gulati, C. Allen
semanticscholar   +1 more source